US OptionsDetailed Quotes
TTOO250117P1500
- 0.00
- 0.000.00%
15min DelayClose Nov 15 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV-201.81%PremiumJan 17, 2025Expiry Date1.00Intrinsic Value100Multiplier61DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
T2 Biosystems Stock Discussion
Sign in to post a comment
$T2 Biosystems (TTOO.US)$
T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year.
Sepsis test panel revenue reached $1.4 million, also increasing 34%.
The company secured 11 T2Dx® Instrument contracts and initiated an exclusive U.S. distribution agreement with Cardinal Health.
Net loss was $10.1 million ($0.57 per share), improving from $15.4 million loss in Q3 2023.
Cash position stood at $2.1 million as of September 30...
T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year.
Sepsis test panel revenue reached $1.4 million, also increasing 34%.
The company secured 11 T2Dx® Instrument contracts and initiated an exclusive U.S. distribution agreement with Cardinal Health.
Net loss was $10.1 million ($0.57 per share), improving from $15.4 million loss in Q3 2023.
Cash position stood at $2.1 million as of September 30...
1
$T2 Biosystems (TTOO.US)$
let's go sit at the bottom again
let's go sit at the bottom again
1
1
2
$T2 Biosystems (TTOO.US)$ T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
1
5
$T2 Biosystems (TTOO.US)$
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
2
1
$T2 Biosystems (TTOO.US)$ Reuters· 6 mins ago
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
$T2 Biosystems (TTOO.US)$
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
1
$T2 Biosystems (TTOO.US)$
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems (NASDAQ: TTOO) announced preliminary unaudited financial results for Q3 2024, reporting a 35% increase in total revenue compared to the prior year period. Key highlights include:
- Total revenue of $2.0 million
- Sepsis test panel revenue of $1.6 million, up 42% year-over-year
- Executed contracts for 11 T2Dx® Instruments
- Expanded international distribution to Malaysia and Indon...
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems (NASDAQ: TTOO) announced preliminary unaudited financial results for Q3 2024, reporting a 35% increase in total revenue compared to the prior year period. Key highlights include:
- Total revenue of $2.0 million
- Sepsis test panel revenue of $1.6 million, up 42% year-over-year
- Executed contracts for 11 T2Dx® Instruments
- Expanded international distribution to Malaysia and Indon...
No comment yet
151765095 : what is the Future prediction??
Jaguar8 OP 151765095 : Still on my watchlist next week. Sometimes there is delayed market reaction
NightMarket : I’m curious how do you keep track of all these ? Do you save it in moomoo watchlist separately ?
Jaguar8 OP NightMarket : I have hundreds of stocks on my list and are categorized. Then I take note of news and add to my notes when needed.
NightMarket Jaguar8 OP : I see. Thanks!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")